Internet-Delivered Cognitive Behavior Therapy for Atopic Dermatitis: A Randomized Clinical Trial.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 Jul 2021
Historique:
pubmed: 20 5 2021
medline: 26 3 2022
entrez: 19 5 2021
Statut: ppublish

Résumé

Atopic dermatitis is a common and debilitating skin condition characterized by intense itching and chronic inflammation. Research on behavioral treatments with high accessibility is needed. To investigate the efficacy of a highly scalable internet-delivered cognitive behavior therapy (CBT) for adults with atopic dermatitis. This randomized clinical trial from a medical university in Stockholm, Sweden, included 102 adults with atopic dermatitis, recruited from across Sweden, who received 12 weeks of internet-delivered CBT (March 29, 2017, to February 16, 2018). The first participant provided screening data on November 27, 2016, and the last 1-year follow-up assessment was conducted on June 28, 2019. Participants were randomized in a 1:1 ratio to 12 weeks of therapist-guided internet-delivered CBT (n = 51) or a control condition (n = 51) that gave instructions about standard care. The primary outcome was the between-group difference in mean reduction of atopic dermatitis symptoms as measured by the Patient-Oriented Eczema Measure and modeled intention to treat during the 12-week treatment period. A total of 102 participants (mean [SD] age, 37 [11] years; 83 [81%] female) were recruited and randomized. The primary analysis indicated that participants receiving internet-delivered CBT, relative to the controls, had a significantly larger mean weekly reduction in symptoms of atopic dermatitis as measured with the Patient-Oriented Eczema Measure (B = 0.32; 95% CI, 0.14-0.49; P < .001), with a moderate to large, controlled effect size after treatment (d = 0.75; 95% CI, 0.32-1.16). Secondary analyses indicated that internet-delivered CBT also produced significantly larger reductions in itch intensity, perceived stress, sleep problems, and depression. Gains were sustained at 12 months of follow-up. Treatment satisfaction was high, and therapists spent a mean (SD) of 39.7 (34.7) minutes per treated patient providing internet-delivered CBT. Internet-delivered CBT appears to be efficacious for reducing symptoms of atopic dermatitis, despite requiring minimal therapist resources. Thus, internet-delivered CBT has the potential to increase access to effective adjunct behavioral treatment for patients with this common skin condition. ClinicalTrials.gov Identifier: NCT03051958.

Identifiants

pubmed: 34009282
pii: 2779785
doi: 10.1001/jamadermatol.2021.1450
pmc: PMC8135053
doi:

Banques de données

ClinicalTrials.gov
['NCT03051958']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

796-804

Auteurs

Erik Hedman-Lagerlöf (E)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Jens Fust (J)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Erland Axelsson (E)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Marianne Bonnert (M)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Maria Lalouni (M)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Olof Molander (O)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Petter Agrell (P)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Anna Bergman (A)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Nils Lindefors (N)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Maria Bradley (M)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH